| Name | Title | Contact Details |
|---|
Ashwood Retirement and Assisted is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Boston Ivf is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Shore Memorial Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Somers Point, NJ. To find more information about Shore Memorial Hospital, please visit www.shorememorial.org
AudioNet is a National Provider Network that sub-contracts with various Hearing Aid networks throughout the country to give eligible members the best selection of product and service under one network administrator. We have successfully sub-contracted with over 5,000 Audiologists/ENTs nationally to meet the contractual requirements of our customers, as well as the members needs. Mandating only the most qualified providers to service our members and monitoring the quality of products rendered, AudioNet is able to bring a level of Provider Accountability to the Hearing Aid industry that has never before been seen. Negotiating for State of the Art digital products within a National Provider Network allows the eligible member a tremendous benefit enhancement of upto Two (2) Standard Digital Hearing Aids, covered in full. The Fee Schedules, Product Models and Styles, etc., approved for distribution In-Network are outlined on this website.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.